Oncotelic Therapeutics Inc (QB) (OTLC) News

https://www.otcmarkets.com/stock/OTLC

https://www.otcmarkets.com/stock/OTLC

https://www.otcmarkets.com/stock/OTLC

OTLC IN PLAY

https://www.otcmarkets.com/stock/OTLC

news: https://www.biospace.com/article/releases/sapu-bioscience-and-cromos-pharma-initiating-p201-a-registrational-trial-for-ot-101-in-pancreatic-cancer/?keywords=pancreatic+cancer+phase+3

OTLC
Oncotelic Therapeutics Inc (QB)
0.023385
-0.000515 (-2.15%)
Volume: 5,220
Day Range: 0.02295 - 0.023385
Last Trade Time: 1:31:48 PM EDT

OTLC
Oncotelic Therapeutics Inc (QB)
0.0205
-0.00035 (-1.68%)
Volume: 320,370
Day Range: 0.0205 - 0.022
Last Trade Time: 4:06:18 PM EDT

OTLC
Oncotelic Therapeutics Inc (QB)
0.0345
0.004 (13.11%)
Volume: 718,034
Day Range: 0.031 - 0.035
Last Trade Time: 4:02:37 PM EDT

OTLC
Oncotelic Therapeutics Inc (QB)
0.033
-0.002 (-5.71%)
Volume: 161,792
Day Range: 0.033 - 0.0355
Last Trade Time: 4:01:43 PM EDT

OTLC
Oncotelic Therapeutics Inc (QB)
0.042
-0.002 (-4.55%)
Volume: 265,396
Day Range: 0.042 - 0.0525
Last Trade Time: 3:21:30 PM EDT

OTLC
Oncotelic Therapeutics Inc (QB)
0.051
0.01 (24.39%)
Volume: 42,028
Day Range: 0.0425 - 0.052
Last Trade Time: 3:41:20 PM EDT

Oncotelic Announces Release of Pet2DAO Tokens (PDAO): https://www.benzinga.com/pressreleases/23/04/g31629187/oncotelic-announces-release-of-pet2dao-tokens-pdao

https://seekingalpha.com/symbol/otcc

https://seekingalpha.com/symbol/onlg

OTLC
Oncotelic Therapeutics Inc (QB)
0.048
-0.00705 (-12.81%)
Volume: 73,296
Day Range: 0.0451 - 0.055
Last Trade Time: 3:55:10 PM EST

OTLC
Oncotelic Therapeutics Inc (QB)
0.048
-0.00705 (-12.81%)
Volume: 73,296
Day Range: 0.0451 - 0.055
Last Trade Time: 3:55:10 PM EST

OTLC
Oncotelic Therapeutics Inc (QB)
0.055
0.001 (1.85%)
Volume: 65,321
Day Range: 0.04815 - 0.055
Last Trade Time: 2:35:44 PM EST

OTLC
Oncotelic Therapeutics Inc (QB)
0.0465
-0.0015 (-3.13%)
Volume: 55,357
Day Range: 0.046 - 0.0495
Last Trade Time: 3:34:32 PM EST

yes /\ Oncotelic Therapeutics Inc.

The balance sheet and cap structure shows that this management team did a toxic financing which means the stock will go down. That is 100% sure to occur because toxic financings benefit the financier because the stock is given by the company to the financier at a discount to market.

The financier sells the stock, even at a lower price than the market and they guarantee themselves a profit.

That is how and why you see 0001 a share price for some stocks.

Another reason this stock will go down is because I once spoke to the CFO - he was is stupid he has no right being an officer of a public company.

I am guessing that he is an accountant and the CEO hired him to be a figurehead.

Anytime a CFO is stupid you get stupid decisions and then the stock goes down.

Charts don't matter.

The balance sheet and cap structure shows that this management team did a toxic financing which means the stock will go down. That is 100% sure to occur because toxic financings benefit the financier because the stock is given by the company to the financier at a discount to market.

The financier sells the stock, even at a lower price than the market and they guarantee themselves a profit.

That is how and why you see 0001 a share price for some stocks.

Another reason this stock will go down is because I once spoke to the CFO - he was is stupid he has no right being an officer of a public company.

I am guessing that he is an accountant and the CEO hired him to be a figurehead.

Anytime a CFO is stupid you get stupid decisions and then the stock goes down.

http://www.stockta.com/cgi-bin/analysis.pl?symb=otlc

https://www.stockscores.com/charts/charts/?ticker=otlc

https://www.otcmarkets.com/stock/OTLC/security

#248
$MATN & $GILD?????,6;41a.m. 07-07-2020 .M. Mateon Therapeutics Appts. mick 07/28/2020 10:25:22 PM

OTLC
Oncotelic Therapeutics Inc (QB)
0.06
0.00355 (6.29%)
Volume: 301,282
Day Range: 0.0551 - 0.06
Bid: 0.0484
Ask: 0.0761
Last Trade Time: 3:53:06 PM EDT
Total Trades: 27
OTLC Detailed Quote

Management is inept

Once I spoke to the CFO and he clearly does not know anything about being a CFO of a public company.

The CEO on the other hand does not understand the importance of letting investors know about his company. He keeps raising capital from investors at such bad terms the only people that will ever make money are his bankers and the people that continue to short the stock.

Some people have no right to raise capital because although they are not a scam, there is no chance of their stock increasing because management is inept or they don't understand the markets.

OTLC
Oncotelic Therapeutics Inc (QB)
0.08077
0.00027 (0.34%)
Volume: 563,673
Day Range: 0.08 - 0.082
Bid: 0.0681
Ask: 0.09
Last Trade Time: 3:44:59 PM EDT
Total Trades: 29
OTLC Detailed Quote

OTLC
Oncotelic Therapeutics Inc (QB)
0.10
-0.003 (-2.91%)
Volume: 292,973
Day Range: 0.10 - 0.103
Bid: 0.098
Ask: 0.10
Last Trade Time: 4:07:43 PM EDT
Total Trades: 37
OTLC Detailed Quote

Surprised at the lack of interest

Looks like we should expect success in the Mesothelioma trial around the six month time frame. I am sure that it will take many would be short players off guard, and make them regret their little games.

Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention: https://finance.yahoo.com/news/oncotelic-announces-pipeline-presentation-ipo-120000848.html

Oncotelic Therapeuti (OTLC)
0.21 ? 0.009 (4.48%)
Volume: 64,267 @06/03/22 3:53:07 PM EDT
Bid Ask Day's Range
0.175 0.224 0.196 - 0.214
OTLC Detailed Quote

nice news...https://www.otcmarkets.com/stock/OTLC/news/Oncotelic-Therapeutics-Receives-FDA-Clearance-for-Phase-2-Clinical-Trial-of-OT-101Pembroluzimab-Combination-for-Mesothel?id=358545

ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE: https://www.globenewswire.com/news-release/2022/05/23/2448615/0/en/ONCOTELIC-PROVIDES-Q1-2022-FINANCIAL-RESULTS-COMPARED-TO-Q1-2021-PRODUCT-DEVELOPMENT-INITIATIVES-AND-CORPORATE-UPDATE.html

Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer: https://oncotelic.irpass.com/Oncotelic-Appoints-Fatih-Uckun--M-D---Ph-D---as-Chief-Medical-Officer-5-3-2022

Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer: https://oncotelic.irpass.com/Oncotelic-Appoints-Seymour-Fein-M-D--as-Chief-Regulatory-Officer-5-4-2022

Oncotelic Therapeuti (OTLC)
0.216 ? -0.0112 (-4.93%)
Volume: 60,460 @04/29/22 3:54:24 PM EDT
Bid Ask Day's Range
0.211 0.2279 0.2123 - 0.2279
OTLC Detailed Quote

$OTLC on watch due to Daily Chart increasing Volume and now crossing the 50 SMA. Accum/Dist on the rise as well.

Recently provided Year 2021 Financial Results:

https://www.globenewswire.com/news-release/2022/04/18/2423605/0/en/ONCOTELIC-PROVIDES-YE-2021-FINANCIAL-RESULTS-COMPARED-TO-YE-2020-PRODUCT-DEVELOPMET-INITIATIVES-AND-CORPORATE-UPDATE.html

$OTLC ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE

AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced financial results for the full year ended December 31, 2021 (“FY 2021”) as compared to the full year ended December 31, 2020 (“FY 2020”), an update on its product and therapeutic development initiatives and other corporate updates. The financial results were based on the 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2022.

https://www.otcmarkets.com/stock/OTLC/news/ONCOTELIC-PROVIDES-YE-2021-FINANCIAL-RESULTS-COMPARED-TO-YE-2020-PRODUCT-DEVELOPMET-INITIATIVES-AND-CORPORATE-UPDATE?id=352529

This Little Known Cancer Play has been Crushing the Market (ADGI, OTLC, DVAX, PACB, SAVA, NVAX, IMGN, BNTX)

https://www.wallstreetpr.com/this-little-known-cancer-play-has-been-crushing-the-market-adgi-otlc-dvax-pacb-sava-nvax-imgn-bntx-46481

This Little Known Cancer Play has been Crushing the Market (ADGI, OTLC, DVAX, PACB, SAVA, NVAX, IMGN, BNTX)

https://www.wallstreetpr.com/this-little-known-cancer-play-has-been-crushing-the-market-adgi-otlc-dvax-pacb-sava-nvax-imgn-bntx-46481

$OTLC Company Profile and Technical Chart Analysis

$OTLC The Accumulation here is off the charts right now. MACD is also triggering a BUY signal, Setup for a significant move now imo.

$OTLC Chart Forming Beautiful BULL FLAG here! Bullish flag formations are found in stocks with strong uptrends and are considered good continuation patterns.

MACD Histogram is above the signal line and increasing which is also bullish. It indicates an increase in upward momentum.

$OTLC Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited

AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following shareholder letter today.

Dear Fellow Shareholders,

We would like to thank you for being part of our mission at Oncotelic which is to develop treatments for cancer patients that have limited options. Our efforts include pursuing broad applications of our technology as well as the treatment of cancer types that are given orphan drug designation (“ODD”) meaning there are a limited number of patients that have a high unmet medical need. We have spent considerable time and effort to unify our collective assets toward the achievement of this goal. This effort included receiving a Rare Pediatric Disease (“RPD”) designation for pediatric cancer which give us access to the RPD voucher on top of the regulatory exclusivity reserved for ODD while we continue strategic planning for broader applications of our technologies. Taken together, these efforts give us the potential to produce a strong return on investment for our shareholders

Earlier this week, we announced together with our partner Dragon Overseas Capital Limited (“Dragon Overseas”), that we have formed a joint venture (the “JV”) for the discovery, development and commercialization TGF-ß therapeutics against all pharmaceutical indications. The JV intends to initially focus on the further development and commercialization of OT-101, including for DIPG as well as pancreatic cancers and glioblastoma, which are devasting diseases with few treatment options. In connection with this, the Company has granted the JV global, exclusive, perpetual, royalty-free license of intellectual property rights, including and in respect of OT-101 (the “License”).

Our TGF-beta drug candidate- OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. We received FDA designation for pediatric designation related to a rare form of pediatric brain cancer known as diffuse intrinsic pontine glioma (“DIPG”). There are approximately 200-300 new cases of DIPG every year in the United States. DIPG most often occurs in children ages 5-10 years old. Treatment options are limited with surgery being contraindicated. Most children do not survive more than 2 years after diagnosis. Currently, the main treatment for DIPG is radiation therapy. Although radiation temporarily improves symptoms in most patients, it is not a cure. Palliative care or quality of life services help patients and families manage pain and other symptoms, promote quality of life, and making difficult decisions including treatment choices and end of life care. At Oncotelic, we are dedicated to the treatment of DIPG and welcome our shareholders on this endeavor.

The anti-viral activity of OT-101, in an in vitro antiviral testing performed by an independent laboratory, OT-101 has an 50% effective concentration (EC50) of 7.6 µg/mL and is not toxic at the highest dose of 1000 µg/mL giving a safety index (SI) value of >130, which is considered highly active and on par or superior to Remdesivir. Unlike Remdesivir, OT-101 targets not only the virus replication but also the virus induced pneumonia and fibrosis. Our Phase 2 trial was completed for OT-101 in South America. This was a randomized, double-blind, placebo-controlled Phase 2 study intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with positive SARS-CoV-2 and pneumonia. As reported on November 23, 2021, the top line data is positive for safety and efficacy.

This transaction allows us to unburden the Company of the high cost of drug development, which the JV will be responsible for, while the Company will participate in its upside through appreciation in the value of its shares in the JV and up to $50MM on the sale of the RPD voucher following marketing approval of OT-101 for DIPG. Dragon Overseas has agreed to invest cash and other assets with a value of approximately $27.6MM for 55% ownership of the JV; and Oncotelic has granted the License to the JV for 45% ownership in the JV.

The fuel needed to drive OT-101 development is robust financing- and the JV provides that. This combination of strong financial backing and strong asset creates a solid foundation for the coming IPO. We believe that the JV IPO will be as successful as other recent IPOs in the TGF-ß space. We believe that there is a substantial upside for the Company due to this JV especially if we are able to have a successful IPO. Your attention is drawn to Litchfield’s analyst, Theodore R. O’Neill’s recent coverage on the Company. (https://www.oncotelic.com/wp-content/uploads/2022/03/OTLC-JV-update.pdf).

In the coming months the team will be transitioning into the JV to ensure continuity of operational excellence. Look for future announcements on clinical trials undertaken by the JV in collaboration with pharmaceutical houses and Key Opinion Leaders “KOLs”. Dr. Anthony Maida, our current CCO, will drive the JV’s clinical development of OT-101 in combination with checkpoint inhibitors including pembrolizumab. Multiple phase 2 clinical trials are intended to be launched with our collaborators. Dr. Maida believes that this Joint Venture provides the resources and financial support for Oncotelic allowing to execute its clinical strategy in multiple solid tumor indications coupled with a robust and thorough bioinformatics assessment leading to upstream targeting, improved clinical responses and insights into agnostic applications.

We appreciate your continued support in our development of cures for orphan and rare diseases. By combining innovative drugs and robust financing we look to transform healthcare one rare disease at a time.

Sincerely yours,

Vuong Trieu and the Oncotelic team

About Oncotelic

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019.

Additionally, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease (“PD”). Over 60,000 new patients are being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics. AL-101 is also being developed for Erectile Dysfunction (“ED”). ED is the most prevalent male sexual disorder globally. The percentages of men affected by ED are as follows: 14.3-70% of men aged ≥60 years, 6.7-48% of men aged ≥70 years, and 38% of men aged ≥80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors. Through similar mechanism of action, AL-101 is being developed for Female Sexual Dysfunction (“FSD”). Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260–269). There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (“HSDD”) in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD – however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore, there is an urgent need for effective therapy against FSD and HSDD.

For more information, please visit www.oncotelic.com

https://www.globenewswire.com/news-release/2022/04/07/2418633/0/en/Letter-to-Oncotelic-Shareholders-on-the-Recently-Completed-Joint-Venture-Transaction-with-Dragon-Overseas-Capital-Limited.html

OTLC a bargain here, The JV will be IPO at significant valuation. The consequences are: 1) OTLC shares will increase in value proportionally as we now own 45% of the JV 2) Those who invest in OTLC will be getting in the IPO on the ground level as OTLC is now proxy to the IPO

news https://www.globenewswire.com/news-release/2022/04/07/2418633/0/en/Letter-to-Oncotelic-Shareholders-on-the-Recently-Completed-Joint-Venture-Transaction-with-Dragon-Overseas-Capital-Limited.html

Oncotelic; Announcing Successful Joint Venture and Diving into Benefits for Shareholders:

Oncotelic presentation at MedInvest Pharmaceutical & Biotechnology Investor Conference:

Oncotelic JV Financing: